Medicine presented me with a grassy, less travelled road that wanted wear. I am yet unsure if it made any difference but as I reach an age that is half the average longevity in my country, it would be a shame if I could not share what an exciting journey that it has been. Somewhere between the wisdom of Frost and Bachchan, I sincerely hope that in the face of uncertainty, my work, as I outline here, will help people look at medicine beyond the undergrowth. Within the vastness of medicine and healthcare, I hope that a realization dawns that no matter the path, there is happiness at the end, and stories of the travel that make all the difference.
patents
A patent is like getting a "no copying" hall pass for your invention, where you and your colleagues get to be the only kids on the playground for 20 years before anyone else gets to play. I am one of the inventors in the following patents.
01
Prodrug-loaded liposomes as in situ theranostic agents (IN201921029504)
03
A substrate for entrapment and detection of bacteria, process for its preparation and a point of care device having the substrate (IN201721046073)
05
A biosensor for point of care detection of bacteria (IN201921009094)
02
Development of cell-free, color changing smart lipid-polymer nanoconstructs for assessment of permeability through biological barrier. (IN201921001397)
04
A biosensor for point of care detection of enzyme (IN201921009096)
06
Point of care device for detection of bacterial enzymes, catalase and beta galactosidase (IN201921009097)
real-world evidence
& advanced analytics
Real-world evidence is data collected from actual patients using treatments in everyday clinical practice (not just controlled studies), and advanced analytics are the sophisticated computer tools and AI/ML methods used to crunch all that messy real-world data to figure out what actually works in the wild.
01
Graff, S. L., Tolaney, S. M., Hart, L. L., Razavi, P., Janni, W., Schwartzberg, L. S., Danyliv, A., Akdere, M., Ferrusi, I., Adhikary, R. R., & O'Shaughnessy, J. A. (2025). Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2- early breast cancer. Cancer, 131(7), e35817. https://doi.org/10.1002/cncr.35817
03
Day, J. W., Mendell, J. R., Burghes, A. H. M., van Olden, R. W., Adhikary, R. R., & Dilly, K. W. (2023). Adeno-associated virus serotype 9 antibody seroprevalence for patients in the United States with spinal muscular atrophy. Molecular therapy. Methods & clinical development, 31, 101117. https://doi.org/10.1016/j.omtm.2023.101117
05
Inati, A., Sabbagh, M., Al Alam, C., Al Kheir, A., Massouh, Z., Demachkie, R., Ojaimy, C., Dani, N., Siddiqui, A., Adhikary, R. R., Lynch, B., & Srivastava, A. (2022). PB2219: Healthcare Resource Utilization patterns and related costs in patients with sickle cell disease in North Lebanon- A Real-World Experience. HemaSphere, 6(Suppl ), 2089-2090. https://doi.org/10.1097/01.HS9.0000851704.30692.ea
02
Graff, S. L., Tolaney, S. M., Hart, L. L., Razavi, P., Janni, W., Schwartzberg, L. S., Danyliv, A., Akdere, M., Ferrusi, I., Adhikary, R. R., & O'Shaughnessy, J. A. (2023). Invasive disease-free survival as a surrogate for overall survival in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative early breast cancer: a real-world analysis. San Antonio Breast Cancer Symposium (SABCS) 2023: PO1-17-07.
04
Kumar, A., Pradhan, H., & Adhikary, R. R. (2022). MSR118 Machine learning approaches towards identification of phenotypes in various diseases using electronic health records. Value in Health, 25(12, Suppl), S372–S373.
https://doi.org/10.1016/j.jval.2022.09.1848
(Poster: ISPOREU22_Adhikary.pdf)
digital therapeutics & SaMD
Digital therapeutics are regulatory-grade apps and software that actually treat medical conditions (like a prescription app for diabetes or hypertension management), while SaMD (Software as Medical Device) is the broader category that includes any software intended to diagnose, treat, or prevent disease - basically turning your smartphone into a mini doctor's toolkit.
01
Verma, R., Adhikary, R.R., Kolwankar, S., Tahilramani, L., Motwani, P., Pawar, S., Bhatt, J., & Shah, A. (2021). Cardiovascular risk reduction in patients with hypertension using a digital therapeutics platform. Journal of the American College of Cardiology, 77(18_Supplement_1), 3215. https://doi.org/10.1016/S0735-1097(21)04570-8
03
Verma, R., Adhikary, R. R., Kolwankar, S., Khatry, V., Venkatachalam, D., Pawar, S., Kavugoli, S., Bhatt, J., Joshi, S., & Saboo, B. (2021). The WELL-8 scale: Assessment of health-related quality of life in people with chronic diseases. Diabetes Technology & Therapeutics, 23(S2), A-1–A-206. https://doi.org/10.1089/dia.2021.2525.abstracts
05
Chawla, R., Aravind, S. R., Adhikary, R. R., Krishnakumar, A., Kolwankar, S., Jaggi, S., Shah, A., & Mattoo, V. (2020). Frequency of interactions with a digital therapeutic platform improves blood glucose control among patients with type 2 diabetes mellitus [Abstract #804846]. Endocrine Practice, 26(Supplement 2), 1–332. https://doi.org/10.1016/S1530-891X(20)39598-7
07
Adhikary, R. R., Joshi, S., Sahay, R.K., & Saboo, B. (2020). Ensuring Continuity-of-care for people with diabetes through Wellthy Care Digital Therapeutics in times of COVID-19. Virtual ADCES2 Conference.
02
Adhikary, R. R., Kolwankar, S., Shah, A., Motwani, P., Pawar, S., & Verma, R. (2021). 593-P: Effectiveness of digital therapeutics to improve clinical outcomes in patients with type 2 diabetes mellitus on insulin therapy. Diabetes, 70(Supplement 1), 593-P.
04
Adhikary, R.R., Krishnakumar, A., Kolwankar, S., Shah, A., Sanghavi, S., & Mattoo, V. (2020). Effectiveness of digital therapeutics to improve blood pressure control among patients with hypertension and diabetes in India. Journal of the American College of Cardiology, 75(11_Supplement_1), 3583.
06
Adhikary, R. R., Kolwankar, S., Shah, A., Motwani, P., Pawar, S., Bhatt, J., & Mattoo, V. (2021). Real-world effectiveness of digital therapeutics toward achieving weight loss in people with obesity and metabolic syndrome. Endocrine Practice, 27(Supplement 2), S77–S78.
08
Krishnakumar, A., Kumar, V., Saboo, B. D., Khatry, V., Joshi, S., Adhikary, R. R., Shah, A., & Mattoo, V. (2020). 907-P: Impact of using a digital therapeutic and blood glucose meter on glycemic control and variability. Diabetes, 69(Supplement 1), 907-P. https://doi.org/10.2337/db20-907-P
translational medicine and
biomedical engineering
These are all bioengineering tools that bridge the gap between lab discoveries and actual patient care: biosensors detect biological signals in your body, biomaterials are specially designed substances that play nice with human tissue, drug delivery systems are smart ways to get medicine exactly where it needs to go, lab-on-a-chip shrinks entire laboratory tests onto a tiny device, and organ-on-a-chip creates miniature artificial organs to test treatments - all working together to translate brilliant scientific ideas into real treatments that save lives.
01
Punjabi, K., Adhikary, R. R., Patnaik, A., Bendale, P., Saxena, S., & Banerjee, R. (2022). Lectin-Functionalized Chitosan Nanoparticle-Based Biosensor for Point-of-Care Detection of Bacterial Infections. Bioconjugate chemistry, 33(8), 1552–1563.
03
Punjabi, K., Adhikary, R. R., Patnaik, A., Bendale, P., Singh, S., Saxena, S., & Banerjee, R. (2020). Core-shell nanoparticles as platform technologies for paper-based point-of-care devices to detect antimicrobial resistance. Journal of materials chemistry. B, 8(29), 6296–6306. https://doi.org/10.1039/d0tb00731e
05
Verma, R., Adhikary, R. R., & Banerjee, R. (2016). Smart material platforms for miniaturized devices: implications in disease models and diagnostics. Lab on a chip, 16(11), 1978–1992. https://doi.org/10.1039/c6lc00173d
07
Adhikary, R. R., Sandbhor, P., & Banerjee, R. (2015). ADMET and DMPK, 3(3), 155-181. https://doi.org/10.5599/admet.3.3.189
02
Adhikary, R. R. & Banerjee, R. (2021). Development of smart core-shell nanoparticle-based sensors for the point-of-care detection of alpha amylase in diagnostics and forensics. Biosensors & bioelectronics, 184, 113244. https://doi.org/10.1016/j.bios.2021.113244
04
Adhikary, R. R., Koppaka, O., & Banerjee, R. (2020). Development of color changing polydiacetylene-based biomimetic nanovesicle platforms for quick detection of membrane permeability across the blood brain barrier. Nanoscale, 12(16), 8898–8908. https://doi.org/10.1039/c9nr07845b
06
Adhikary, R. R., More, P., & Banerjee, R. (2015). Smart nanoparticles as targeting platforms for HIV infections. Nanoscale, 7(17), 7520–7534. https://doi.org/10.1039/c5nr01285f
projects
and
pipeline
Between "what is" and "what is not", there are always "what could have been", that never make it to the spotlight. But here, they have a nook for themselves.
01
Development of a program using Lab Windows™/CVI for heart rate determination and recognition of normal and abnormal ECG signals
03
Study of depression among M.Tech. students in IIT Bombay
05
Piezoelectricity and its use in ultrasound
07
Impact of stroke on quality of life of family members and family function of the patient
09
Use of Integrated Management of Neonatal and Childhood Illness (IMNCI) based modules for Interpersonal Communication in improving feeding practices in children below 3 years at Dhotra Railway village in rural India
02
Microfabricated Retinal Implants;
04
Ultrasound Responsive Nanocarriers for Imaging and Triggered Drug Delivery in Cancers
06
A Study of Evidence underlying the Prescription of Salt Restriction in Hypertensive patients- A Mathematical Viewpoint
08
Management practices of acute coronary syndrome in an intensive care unit: do we follow the standard guidelines?
10
Drug susceptibility test in patients with smear- positive pulmonary tuberculosis: A cost-effective analysis